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Lupus nephritis, one of the most serious manifestations of systemic lupus erythematosus (SLE),
has a heterogeneous clinical and pathological presentation. For example, proliferative nephritis
identifies a more aggressive disease class that requires immunosuppression. However, the current
classification system relies on the static appearance of histopathological morphology, which does
not capture differences in the inflammatory response. Therefore, a biomarker grounded in the
disease biology is needed in order to understand the molecular heterogeneity of lupus nephritis
and identify immunologic mechanism and pathways. Here, we analyzed the patterns of 1000 urine
protein biomarkers in 30 patients with active lupus nephritis. We found that patients stratify over
a chemokine gradient inducible by IFN-γ. Higher values identified patients with proliferative lupus
nephritis. After integrating the urine proteomics with the single-cell transcriptomics of kidney
biopsies, we observed that the urinary chemokines defining the gradient were predominantly
produced by infiltrating CD8+ T cells, along with natural killer and myeloid cells. The urine
chemokine gradient significantly correlated with the number of kidney-infiltrating CD8+ cells.
These findings suggest that urine proteomics can capture the complex biology of the kidney in
lupus nephritis. Patient-specific pathways could be noninvasively tracked in the urine in real time,
enabling diagnosis and personalized treatment.
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Lupus nephritis is one of the most severe manifestations of systemic lupus erythematosus (SLE) (1). Lupus
nephritis affects up to 50% of patients, leading to end-stage renal disease in 10%, and carries an 8-fold
increase in mortality compared with the general population (2–8). Since nephritis is usually asymptomatic,
patients with SLE are serially screened for the presence of abnormal urine protein (9). When proteinuria
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is elevated, a renal biopsy is obtained to confirm the diagnosis and guide treatment. Histopathology classifications subgroup lupus nephritis into 6 classes based on the presence, amount, and location of inflammation and fibrosis (10). For example, the presence of intraglomerular immune cell infiltration (classes III
and IV) identifies the most aggressive proliferative form of SLE nephritis, which is treated with stronger
immunosuppression. Membranous glomerulonephritis (class V) is characterized by thickened glomerular
basal membranes, subepithelial immune complex deposition, and absence of intraglomerular infiltration.
Endocapillary proliferation and membranous disease frequently overlap in the “mixed” phenotype.
Although the current treatment approach to lupus nephritis is loosely grounded in the morphological
classification, findings from recent studies have challenged this paradigm. Kidney biopsies repeated after 1
year showed a transition in class in up to 70% of cases, from nonproliferative to proliferative and vice versa,
with the second biopsy having better prognostic value (11, 12). These findings indicate that lupus nephritis is a dynamic process, and therefore disease state inferred from kidney biopsies at one time point may
have a limited value. In addition, recent studies have underscored the prognostic importance of interstitial
disease, which is inadequately addressed by current histologic classification schemes (13). Finally, routine
histopathology of lupus nephritis cannot evaluate the underlying molecular pathways that may inform
personalized treatment choices. Recent single-cell RNA-Seq studies have revealed the complex network of
immune cells, and their diversity, in the context of lupus nephritis (14–16). These studies offer promise for
more personalized strategies for therapeutics and for prevention of renal fibrosis.
As patients with the same histological class may have dramatically different outcomes (17), there is
an unmet need for a new biology-based classification of lupus nephritis that can dissect the heterogeneity.
Ideally, such immunologic classification needs to be easily queried during the course of the disease to
dynamically assess changes in response to intervention over months (rather than year). Several previous
studies explored potential biomarkers to assess and predict lupus nephritis by using targeted and systematic
proteomics approaches (18–21). However, these have not yet been standardized for clinical practice and
do not consider lupus nephritis biological endotypes (18). In this study, we sought to identify patterns in
the urine proteome that can identify distinct groups of SLE patients and infer the ongoing renal molecular pathology. We quantified 1000 urine protein biomarkers in active lupus nephritis and identified that
patients stratify on an immune activation gradient. Integration with renal single-cell RNA-Seq revealed that
the urine signature reflected intrarenal secretion by immune infiltrating cells and that IFN-γ is a main driver
of such increased immune activation.

Results
Urine proteomics stratifies lupus nephritis patients on an immune activation gradient. This study was initiated
to address whether we could classify lupus nephritis patients based on distinct biological patterns in the
urine. We quantified 1000 analytes, including cytokines, growth factors, and other soluble markers, in
urine samples from 30 SLE patients with proteinuria and kidney biopsy samples taken on the same day
confirming lupus nephritis (class III, IV, or V), as part of phase 1 of the Accelerating Medicines Partnership (AMP; Table 1 and Supplemental Figure 1; supplemental material available online with this article;
https://doi.org/10.1172/jci.insight.138345DS1) (14). To determine patterns of inflammation in an unbiased manner, we used principal component analysis (PCA), a dimension reduction technique that identifies major axes of variation in the urine proteome. For example, the first 2 principal components (PCs)
clearly separated healthy donors from SLE patients based on distinct patterns of urinary protein excretion
(Supplemental Figure 2). Within lupus nephritis, the first PC (PC1) stratified patients on a gradient rather
than distinct clusters (Figure 1A). We noted that patients with higher PC1 values were more likely to have
proliferative lupus nephritis, while the patients with pure membranous lupus nephritis had PC1 values
that were close to 0 or negative (Figure 1, A and B), suggesting that PC1 detected a biological response
shared by many patients with proliferative lupus nephritis. No association was detected between PC1 and
demographics or technical confounders such as batch, proteinuria, age, or sex. There was no association
with prednisone use or dosage (Supplemental Figure 3). PC2 was associated with site of urine collection
(Supplemental Figure 4), and therefore it was not evaluated further.
Next, we sought to characterize the biological significance of the PC1 gradient. As PCs are determined by the weighted sum of all the analytes, we tested whether a molecular pathway was enriched
using the weight (“loading”) of each analyte on PC1 (Figure 1C). Gene set enrichment analysis (GSEA)
revealed that PC1 detected chemotaxis pathways (FDR < 0.01) (Figure 1D and Supplemental Figure 5):
insight.jci.org   https://doi.org/10.1172/jci.insight.138345
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Table 1. Demographics and clinical characteristics
Characteristic

Age
Female
Race/ethnicity
African American
White
Asian
Other
Anti-dsDNA
Low complement
Lupus nephritis class
III or IV
V
III+V or IV+V
Histological features (n = 19)
Activity
Chronicity
Proteinuria, mg/g
Response to treatment at 12 months
Treatment at time of biopsy
Hydroxychloroquine
Corticosteroids
Mycophenolate
Belimumab

n (%)/mean (range)

33.5 (19–54) yr
28 (93%)
12 (40%)
10 (33%)
7 (23%)
1 (3%)
24 (80%)
26 (87%)
14 (47%)
9 (30%)
7 (23%)
3 (0–12)
1 (0–4)
2.6 (0.53–11.6)
6 (20%)
26 (87%)
19 (63%)
1 (3%)
2 (7%)

in particular, a pattern of chemokines secreted in response to IFN-γ, IL-1β, and TNF and directed to
attract monocytes, NK cells, and CD8+ T cells.
Together, these findings indicate that urine proteomics analyses identified differential expression of a
specific immune activation signature in patients with lupus nephritis and that stronger signals were associated with proliferative lupus nephritis.
Urine cytokines reflect intrarenal production by myeloid and cytotoxic lymphocytes. We asked whether
the chemokines detected in the urine were indicative of intrarenal production by kidney-infiltrating
immune cells. To answer this question, we analyzed single-cell transcriptomics from 24 renal biopsies
of patients with lupus nephritis (Figure 2, A and B) (14). We carried out single-cell transcriptomic
analysis on genes coding for the proteins found in 2 of the most enriched pathways in the urine PC1
(“chemokine-mediated signaling pathway,” GO:0070098; and “cellular response to interferon-gamma,”
GO:0071346) (Supplemental Figure 6) in the renal cells. A chemokine score was defined as the sum
of the normalized expression of the aforementioned genes. While these chemokines were expressed by
most infiltrating immune cells as well as epithelial cells, dominant expression was observed in myeloid,
NK cells, and CD8+ T cells (Figure 2, C–F).
To evaluate whether the proteins found in the urine derived from serum as a consequence of glomerular or tubular damage, we repeated the analysis after adjustments for albumin or β2-microglobulin, respectively. Results were virtually identical to the unadjusted analysis (Supplemental Figure 7).
These findings suggest that the chemokines identified by urine proteomics derive from intrarenal
chemokine production particularly by myeloid, NK, and CD8+ T cells.
IFN-γ is mostly produced by infiltrating CD8+ and NK cells in all patients with lupus nephritis. Pathway
analysis indicated a chemokine pattern inducible by IFN-γ, IL-1β, or TNF. We quantified kidney-infiltrating cells expressing such cytokines. Of the 3 cytokines, IFN-γ–positive cells were the most abundant, followed by TNF and IL-1β (Figure 2G). IFN-γ was mostly produced by CD8+ T and NK cells;
TNF by myeloid, CD8+, and CD4+ T cells; and IL-1β almost exclusively by myeloid cells (Figure 2,
B and H). Local transcription of these cytokines suggests that their transcriptional signatures in the
kidney and protein levels in the urine are a direct consequence of intrarenal production. Since patients
insight.jci.org   https://doi.org/10.1172/jci.insight.138345
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Figure 1. Lupus nephritis patients stratify over an immune activation gradient. (A and B) PCA (n = 30) of the first 2 PCs of the urine proteome (%
variance explained is indicated). Patients with higher PC1 value almost exclusively have proliferative lupus nephritis (class III, IV, or mixed). P value
calculated by t test. (C) Top and bottom 10 PC1 loading values of the measured urine protein. (D) Top 10 enriched pathways detected by PC1 using
Gene Ontology Biological Process, indicating the biological significance of PC1.

contributed a different number of cells to the data set, we evaluated whether these findings were biased
by a small number of patients contributing more cells. IFN-γ+ cells were identified in all patients, ranging between 4% and 45% of the total immune cells (mean 18%); TNF+ cells in 4%–32% (mean 16%);
and IL-1β+ in 0%–13% (mean 7%) (Table 2 and Supplemental Figure 8). In contrast, we did not detect
any transcription of type 1 IFNs (Figure 3) or type 2 immunity (Th2) cytokines such as IL-4, IL-5,
or IL-13 (Supplemental Figure 9), suggesting that a type 1 (Th1) immune response (22) is ubiquitous
in patients with lupus nephritis including nonproliferative histological classes and that IFN-γ (type 2
IFN) is the main IFN being produced by immune cells in lupus kidney disease.
Urine proteomics may predict the intrarenal cellular infiltrate. We then hypothesized that urine proteomics could be used to infer the composition of kidney-infiltrating cell types in lupus nephritis. We
analyzed 6 patients with matching urine proteomics and single-cell transcriptomics on a renal biopsy
sample collected the same day. Of these, 4 patients were diagnosed with proliferative lupus nephritis
(including mixed) and 2 with pure membranous lupus nephritis based on histopathology (Figure 4A).
Single-cell transcriptomics revealed a heterogenous cellular infiltrate regardless of histopathological
class (Figure 4B). We found that urine proteomics PC1 values strongly correlated with the relative
abundance of kidney-infiltrating CD8+ T cells (r2 = 0.84, P < 0.01; Figure 4C). There was no statistically significant correlation with the other cell populations. While needing validation in a larger cohort,
these findings suggest that urinary protein patterns would predict the cell composition of the renal
immune infiltrate in lupus nephritis and that CD8+ T cells, the major producer of IFN-γ, may be the
key contributor of the immune activation signature in the urine.

Discussion
Urine is an ideal noninvasive specimen for repetitive assessment of lupus nephritis. It contains the by-products of the ongoing renal biological processes in real time, is highly noninvasive, and can be easily monitored over time. Here, we show that urine proteomics in patients with lupus nephritis may detect biologically relevant pathways that are mirrored in the kidney tissue. We found that (i) patients with higher
expression of urinary chemokine and immune activation pathways almost exclusively have proliferative
lupus nephritis; (ii) these chemokines are renally produced by infiltrating myeloid, NK, and CD8+ T cells;
and (iii) urine proteomics may predict the composition of the renal cellular infiltrate.
The current classification of lupus nephritis relies on morphological features that may not fully capture the complex, dynamic, and heterogeneous biology. We showed that systematic, unbiased analysis of
the urine proteome may reveal the active immunological pathways in the kidney. Not surprisingly, patients
insight.jci.org   https://doi.org/10.1172/jci.insight.138345
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Figure 2. The chemokine pathway detected by urine proteomics reflects intrarenal production by myeloid, CD8+, and NK cells. (A) Uniform manifold approximation and projection (UMAP) plot of single-cell RNA-Seq of 24 renal biopsies of patients with active lupus nephritis (medium resolution
clustering). (B) The identity of the cell clusters was determined by the expression of lineage markers. (C–F) A chemokine and an IFN-γ response score
based on the expression of the markers in the top urine PC1 pathways (“chemokine-mediated signaling pathway,” GO:0070098; and “cellular response to
interferon-gamma,” GO:0071346)) identified kidney-infiltrating myeloid, CD8+, and NK cells as the main producers of the chemokines in response to IFN-γ
detected in the urine. (G) Distribution of IFN-γ–, TNF-, and IL-1β–expressing cells. (H) Distribution of the total unique molecular identifiers (UMIs) mapped
to IFN-γ, TNF, and IL-1β as a proxy for the amount of cytokine produced by each cell type.

with a stronger chemokine signal in the urine have glomerular immune cell infiltration, as seen in proliferative lupus nephritis. Strikingly, the chemokines detected are part of a specific immune response inducible
by IFN-γ, IL-1β, and TNF that matches the inflammatory environment in the kidney. The universal and
numerically substantial presence of IFN-γ–positive cells suggests a strong type 1 (Th1) immune response
(22). In fact, the analysis of the single-cell transcriptome of kidney-infiltrating immune cells revealed IFN-γ
production in all patients, but not type 2 (Th2) response cytokines (IL-4, IL-5, and IL-13). Furthermore, the
IFN-γ–inducible urinary PC1 strongly correlated with the predominance of infiltrating CD8+ T cells, the
major source of IFN-γ in lupus nephritis. Together, these findings suggest an ongoing IFN-γ–driven response
in the kidneys of patients with lupus nephritis (supporting the presence of nonexhausted T cells), which
can be detected in real time in the urine by measurement of chemokines. These chemokines are directed
to attract mostly macrophages, neutrophils and lymphocytes, and especially other IFN-γ–producing cells
via ligation of CXCR3, CXCR4, and CCR5 that may amplify the immune response in a feed-forward loop.
We performed an unsupervised analysis to detect biology-driven differences rather than looking for
markers that associated with prespecified outcomes such as histological class. While a stronger immune
insight.jci.org   https://doi.org/10.1172/jci.insight.138345
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Table 2. Prevalence cytokine-positive cells based on single-cell RNA-Seq
Class

IFNG

TNF

IL1B

Cell (n)

III
III
III
III+V
III+V
IV
IV
IV+V
IV+V
IV+V
IV+V
IV+V
IV+V
IV+V
V
V
V
V

17.0%
12.5%
10.8%
18.2%
16.7%
24.7%
30.0%
3.8%
13.3%
15.4%
45.0%
11.7%
22.1%
16.3%
14.8%
18.2%
15.1%
13.7%

15.0%
10.1%
10.8%
15.3%
22.2%
25.8%
32.1%
3.8%
20.0%
7.7%
16.0%
21.8%
14.0%
17.5%
16.0%
11.5%
13.2%
11.4%

0.9%
4.7%
3.3%
3.5%
0.0%
0.0%
9.1%
7.7%
6.7%
7.7%
10.4%
13.4%
2.3%
6.4%
0.0%
8.0%
8.0%
7.8%

440
297
120
170
18
97
243
26
15
13
338
179
86
251
81
286
212
219

activation signal in the urine identified patients with proliferative lupus nephritis, a substantial group of
patients classified as proliferative were grouped with patients with nonproliferative disease. Compared with
those with an elevated immune activation signal, these patients may represent those whose nephritis differs
in the molecular pathways involved, or those in a different stage of the inflammatory process. It is also
conceivable that investigation of the relevant molecular pathways would provide a better assessment of
the disease process in lupus nephritis compared with the current classification system based on glomerular endocapillary infiltration in histology. Since histological class may vary in more than 50% of patients
on re-biopsy, the dynamic identification of precise disease-driving pathways may better inform treatment
selection, development of new treatments, and patient selection for clinical trials. Urine proteomics might
also obviate biopsy sampling error. The next phase of AMP studies is aimed to molecularly dissect lupus
nephritis and reclassify it based on disease biology.
Our results highlight the importance of IFN-γ in lupus nephritis as a potential driver and coverable
therapeutic target. For example, an increase in IFN-γ activity is the first abnormality detected, years
before the diagnosis of SLE, preceding the appearance of autoantibodies and the dysregulation of
type 1 IFNs (23). IFN-γ receptor polymorphisms are linked to the risk of developing SLE; and IFN-γ
polymorphisms result in increased production of IFN-γ that predisposes SLE patients to developing
proliferative rather than membranous lupus nephritis (24, 25). The immune response in proliferative
lupus nephritis has in fact been shown to be skewed toward the Th1 axis, which is IFN-γ predominant
(24, 26, 27). In mouse models, IFN-γ is a crucial cytokine for the development of lupus nephritis, and
its blockage prevents and ameliorates kidney disease as well as reducing mortality (28–30). Strikingly,
type 1 IFNs are not required for the generation of germinal centers and the development of lupus
nephritis in some mouse models, in contrast to IFN-γ signaling (30). IFN-γ has a very pleiotropic effect
involving cellular events implicated in lupus nephritis, including the recruitment and activation of neutrophils, CD8+ and CD4+ T cells, NK cells, and macrophages (31). Importantly, this molecule induces
the formation of germinal centers, T follicular helper cell development, and class switch in B cells (32).
In the gut, IFN-γ mediates the death of intestinal stem cells, suggesting that a similar mechanism may
have implications for irreversible kidney damage and fibrosis (33). In humans, encouragingly positive
phase II trials showed the efficacy of blocking the IFN-γ pathway in extrarenal lupus (34–36). In an
ustekinumab trial, for example, clinical response was associated with reduction of the IFN-γ signature,
rather than type 1 IFN (37). In aggregate, these findings suggest that IFN-γ is a central cytokine in lupus
nephritis, and, given the acceptable safety profile of its direct blockage (38), further studies in lupus
nephritis should pursue IFN-γ inhibition.
insight.jci.org   https://doi.org/10.1172/jci.insight.138345
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Figure 3. Type 2 IFN (IFN-γ), but not type 1 (IFN-α or IFN-β), is expressed in lupus nephritis kidney. Violin plots of the expression of type 1 (IFNA1 and
IFNB1) and type 2 (IFNG) IFNs by single-cell RNA-Seq. No other type 1 IFN (i.e., IFNA2–21, IFNB3, IFNK, etc.) was detected (data not shown).

An IFN gene response, especially type 1, is the archetypal signature of SLE (39–41). We and others
have previously showed a strong type 1 IFN signature in lupus nephritis (14–16). There is a large overlap
between the gene signatures induced by type 1 and type 2 IFNs (42–44), as indicated by shared signaling
pathways. Each IFN type can induce the production of the other one (43), eventually leading to stimulation from both sides and thus a mixed signature. Here, we showed the presence of IFN-γ–producing cells
in lupus nephritis along a typical chemokine signature in the urine, suggesting that IFN-γ is central to the
pathogenesis of lupus nephritis. Type 1 IFN intrarenal transcripts were not detected in our studies, suggesting that, assuming the absence of technical limitations, type 1 IFNs may originate outside the kidney or
arise prior to the clinical events leading to a kidney biopsy.
We acknowledge the limitations of our study. We did not detect an association with clinical variables such as renal activity/chronicity or medication use. There are likely other major detectable
molecular pathways that could identify distinct patient groups. However, the relatively limited sample
size did not allow for further exploration without the risk of a type 1 error. Nevertheless, our findings
are confirmed by other smaller and independent studies that assessed the concentration of a fraction
of our analytes in the urine of patients with lupus nephritis (45). Further studies, as those ongoing
with the phase 2 of the AMP, are needed to extend and validate these results. Second, while our platform did not assay the whole urine proteome, it allowed for interpretability, a broad assessment of
the immune response, and limited major confounders from batch effect and unalignable peptides, as
commonly seen in classical mass spectrometry experiments. To limit this bias, we used a self-contained
enrichment strategy (GSEA). In order to identify protein patterns independently of the amount of
proteinuria, we scaled the analyte concentration within and between patients. As this might introduce
a bias related to this data set, a larger study will be needed to validate the findings and to develop a
convenient assay to apply in clinical practice. However, the high level of infiltrating IFN-γ–producing
cells supports the biological plausibility of our results. Finally, the single-cell RNA-Seq did not include
certain cell types, such as stromal and epithelial cells. These cells were underrepresented by design
in order to enrich for immune cells but are an important source of cytokines and will be evaluated in
future studies. Neutrophils were also not detected, likely because they did not survive the freeze-thaw
process. However, urine proteomics detected a chemokine pattern implicated in neutrophil recruitment consistent with their known involvement in lupus nephritis (46).
In summary, we demonstrated that the complex molecular biology in kidney biopsies could be captured
in urine samples from patients with lupus nephritis. These processes provide insight into patient-specific
disease pathogenesis that can address the issue of heterogeneity in SLE. These pathways can be tracked in
the urine in real time and may not only improve diagnosis but also guide selection, dosing, and monitoring
of treatment, thus paving the way to developing a biologically grounded liquid biopsy.

insight.jci.org   https://doi.org/10.1172/jci.insight.138345
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Figure 4. Urine proteomics may predict the intrarenal cellular infiltrate. Six patients had matching urine proteomic and single-cell RNA-Seq data.
Their coordinates on the urine proteomics PCA shown in Figure 1 are plotted in A. (B) Distribution of kidney-infiltrating immune cells determined by
single-cell RNA-Seq. Patients are ordered based on their urine proteomics PC1 value as they appear in A. (C) Correlation of the urine PC1 values and
the frequency of kidney-infiltrating CD8+ T cells.

Methods
Patients and sample collection. This study enrolled SLE patients with urine protein/creatinine ratio greater
than 0.5 undergoing clinically indicated renal biopsy. Only patients with a pathology report confirming
lupus nephritis were included in the study. Renal biopsies were scored by a renal pathologist according to
the International Society of Nephrology/Renal Pathology Society (ISN/RPS) guidelines and NIH activity
and chronicity scales. Urine specimens were acquired at 2 clinical sites in the United States (Johns Hopkins
University and New York University). The total urine volume was split into two 50-mL Falcon tubes. Urine
cells were pelleted by centrifugation at 200 g for 10 minutes, and the supernatant was aliquoted and stored
at –80 °C. Serological features and complement levels were determined at the clinical visit preceding the
biopsy. Proteinuria was measured on or near the day of the biopsy.
Urine Quantibody assay. The Kiloplex Quantibody protein array platform (QAH-CAA-X00, RayBiotech
Life) was used for screening urine samples. The array was spotted with 1000 capture antibodies specific
for 1000 different proteins in quadruplicate. All urine samples were clarified by centrifugation, and then
diluted to yield a total protein concentration within the working range (0.5–1 mg/mL) before application
to the arrays. Briefly, protein standards and urine samples were incubated on the array for 2 hours to allow
the proteins to bind to the capture antibodies. A biotinylated antibody cocktail comprising 1000 detection
antibodies was subsequently added for incubation for 2 hours. Finally, streptavidin-Cy3 was added and left
to incubate for 1 hour. Washing was performed between each step to remove the unbound reagents. After a
final wash and dry, the slides were read with a fluorescence scanner, and data were extracted from the image
using a vendor-provided GAL file with suitable microarray analysis software. Creatinine was measured for
each urine sample (KGE005, R&D Systems), and all data were creatinine normalized before analysis. For
the complete list of the analytes measured in the urine, see “Kiloplex targets” in the supplemental material.
Renal tissue single-cell RNA-Seq. Renal tissue was collected, stored, and processed as previously described
(14). Briefly, research biopsy cores were collected from consented subjects as an additional biopsy pass or
tissue from routine clinical passes. Only biopsies with confirmed lupus nephritis were included. Kidney
tissue was frozen on site and shipped to a central processing location, where it was thawed and disaggregated. Individual cells were retrieved and sorted by flow cytometry. For each sample, 10% was allocated to
insight.jci.org   https://doi.org/10.1172/jci.insight.138345
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sort CD10+CD45− epithelial cells as single cells, and the remaining 90% was used to sort CD45+ leukocytes
as single cells. For each single cell, the whole gene expression profile was sequenced using the CEL-Seq2
method (47). The relative abundance of the cell clusters was calculated as the proportion of cells annotated
to one cluster over all the immune cells for each patient. The data reported in this article, including the clinical and serological data of the study participants, have been deposited in the ImmPort repository (accession
SDY997). The raw single-cell RNA-Seq data have been deposited in dbGAP (accession phs001457.v1.p1)
Statistics. PCA: Urine protein concentrations were scaled (Z-normalized) within and across patients
after log normalization. Scaling within samples favors the identification of the sample-specific pattern of
expression regardless of the total urine protein concentration. PCs were computed using the R Project
statistics package version 3.5.2.
Pathway enrichment analysis: GSEA (48) was performed using the genes coding for the protein assessed
by the Quantibody assay using the Gene Ontology Biological Process database (49, 50). Pathways with at
least 10 (but fewer than 500) genes represented in the Quantibody assay were included in the analysis.
Enrichment P values were computed based on 10,000 permutations and adjusted for multiple comparisons
using the Benjamini-Hochberg procedure (i.e., FDR) (51). The pathways captured by PC1 were determined
based on the loading of each analyte on PC1. Adjusted P values less than 0.05 were considered significant.
Study approval. Human study protocols were approved by the institutional review boards at Johns Hopkins University and New York University, and written informed consent was received from all participants.
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